rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BBIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End – Company Announcement
      Nov 12Financial TimesBBIO
      These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results
      Nov 11BenzingaBBIO
      BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
      Nov 11Yahoo FinanceBBIO
      BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
      Nov 6Yahoo FinanceBBIO
      What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?
      Nov 1Yahoo FinanceBBIO
      BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says

      BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr

      Oct 30Yahoo FinanceBBIOUBS
      UBS reiterates BridgeBio stock rating on strong Attruby sales
      Oct 30Investing.comBBIO
      BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summary
      Oct 30Yahoo FinanceBBIO
      BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record $1. ...
      Oct 30Yahoo FinanceBBIO
      What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
      Oct 30Yahoo FinanceBBIO
      Earnings call transcript: BridgeBio beats Q3 2026 estimates as revenue jumps 192%
      Oct 29Investing.comBBIO
      BridgeBio Pharma earnings beat by $0.14, revenue topped estimates
      Oct 29Investing.comBBIO
      BridgeBio Pharma Q3 2026 Earnings Call Transcript
      Oct 29BenzingaBBIO
      BridgeBio Pharma Q3 Net Loss Narrows, Revenue Rises
      Oct 29Yahoo FinanceBBIO
      BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

      The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

      Oct 29Yahoo FinanceBBIO
      BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
      Oct 29Yahoo FinanceBBIO
      BridgeBio Pharma: Q3 Earnings Snapshot

      (BBIO) on Thursday reported a loss of $56.The Palo Alto, California-based company said it had a loss of 42 cents per share.

      Oct 29Yahoo FinanceBBIO
      BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
      Oct 29Yahoo FinanceBBIO
      BridgeBio earnings up next: Can Attruby sustain momentum?
      Oct 29Investing.comBBIO
      BridgeBio Pharma (BBIO) Receives a Buy from Cantor Fitzgerald

      Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailBBIO
      BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
      Oct 22Yahoo FinanceBBIO
      The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
      Oct 21Yahoo FinanceBBIOBIIBNTLA
      What BridgeBio Pharma Doubters Missed
      Oct 20Yahoo FinanceBBIO
      4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
      Oct 20Yahoo FinanceBBIO
      Oppenheimer Adjusts Price Target on BridgeBio Oncology Therapeutics to $16 From $22, Maintains Outperform Rating
      Oct 20Yahoo FinanceBBIO
      BridgeBio Pharma (BBIO) Draws Fresh Attention, Is The Pullback A Valuation Opportunity?
      Oct 20Yahoo FinanceBBIO
      Where Does BridgeBio Pharma (BBIO) Value Sit After Trial Wins?
      Oct 20Yahoo FinanceBBIO
      How Pipeline Progress Will Impact BridgeBio Pharma (BBIO) Investors
      Oct 20Yahoo FinanceBBIO
      BridgeBio Pharma (BBIO) Unveils Acoramidis Data As Rare Disease Pipeline Nears Key Reviews
      Oct 20Yahoo FinanceBBIO
      BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
      Oct 19Yahoo FinanceBBIOCYTK
      BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff (NASDAQ:BBOT)
      Oct 19Seeking AlphaBBIO
      BofA Securities Lowers Price Target on BridgeBio Pharma to $102 From $104, Maintains Buy Rating
      Oct 19Yahoo FinanceBBIO
      BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
      Oct 16Yahoo FinanceBBIO
      UBS Adjusts Price Target on BridgeBio Pharma to $92 From $82, Maintains Buy Rating

      BridgeBio Pharma (BBIO) has an average rating of buy and mean price target of $111, according to ana

      Oct 15Yahoo FinanceBBIO
      H.C. Wainwright reiterates Buy on BridgeBio stock, cites trial data
      Oct 15Investing.comBBIO
      BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
      Oct 13Seeking AlphaBBIO
      Truist previews biotech earnings with focus on Insmed, BridgeBio
      Oct 12Investing.comBBIOINSMTFC
      BridgeBio's Encaleret Shows Symptoms, Bone Turnover Improvements in Phase 3 Trial in ADH1
      Oct 12Yahoo FinanceBBIO
      BridgeBio's Acoramidis Linked to Promising Clinical Outcomes in Real-World Study
      Oct 12Yahoo FinanceBBIO
      BridgeBio Pharma Has Lost 28% Since July: Barclays Sees 139% Upside
      Oct 12Yahoo FinanceBBIOBCS
      BridgeBio presents encaleret trial data, doses first patient
      Oct 11Investing.comBBIO
      BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug (BBIO:NASDAQ)

      BridgeBio (BBIO) Phase 3 encaleret results in ADH1 show symptom and bone-health gains; FDA priority review decision May 2027—read key investor takeaways.

      Oct 11Seeking AlphaBBIO
      Projecting Big Growth For This $13 Billion Biotech Name

      Here is how to initiate a holding in the name with a covered call order.

      Oct 11TheStreetBBIO
      RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

      Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailBBIO
      FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
      Oct 7Yahoo FinanceBBIO
      H.C. Wainwright reiterates BridgeBio stock rating on FDA filing
      Oct 7Investing.comBBIO
      BridgeBio Pharma stock rating reiterated at Buy by Canaccord
      Oct 7Investing.comBBIO
      BridgeBio to present encaleret trial data at medical meeting
      Oct 6Investing.comBBIO
      BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

      PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Mas

      Oct 6Yahoo FinanceBBIO
      BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
      Oct 6Yahoo FinanceBBIO

      This is the newest page. Registered accounts read further back.